Perimenopause: Symptom Tracker & Hormonal Testing
If you are in your 40s and something feels off — your periods are showing up early, late, heavy, light, or not at all; you are waking at 3 a.m. drenched in sweat; your previously reliable brain has started forgetting why you walked into the kitchen; and your PMS has turned into a two-week monster — you are very likely in perimenopause. And if you asked your doctor for a blood test to confirm it, they probably drew an FSH and estradiol, got a result that said "normal, still premenopausal," and sent you home feeling crazy. You are not crazy. The test was simply the wrong tool for the question.
Perimenopause is the transitional years before your final menstrual period — typically beginning in the mid-40s and lasting on average four to eight years, though it can span anywhere from two to fourteen. During this window, your ovaries do not gracefully ramp down; they sputter. Estrogen levels swing wildly from week to week, sometimes hour to hour. That swinging — not a simple deficiency — is what produces the symptoms. And it is exactly why a single blood draw on a single morning is almost useless for diagnosis in a woman over 45 with a uterus and ovaries.
This guide walks through what perimenopause actually looks like, why the standard hormone panel misleads patients and clinicians alike, when testing does help, the overlap conditions that masquerade as perimenopause (thyroid, iron, B12, vitamin D), and a practical three-month symptom-tracking template you can start today — the single most useful diagnostic tool available to you.
Table of Contents
- Stages of Perimenopause (STRAW+10)
- The Symptom Constellation
- Why FSH and Estradiol Testing Misleads
- When Testing Actually Helps
- Overlap Conditions That Mimic Perimenopause
- A Practical 3-Month Symptom Tracker
- Cycle- and Symptom-Tracking Apps
- When to Start HRT vs. Wait
- Key Research Papers
- PubMed Topic Searches
- Connections
Stages of Perimenopause (STRAW+10)
The Stages of Reproductive Aging Workshop + 10 (STRAW+10) criteria, updated in 2012, are the international gold standard for describing where you are in the menopause transition. STRAW+10 uses menstrual cycle patterns as the primary marker and treats hormone levels as secondary — precisely because cycles tell the truth more reliably than a single blood test. The key stages:
- Late Reproductive (Stage -3): Cycles still regular but subtly changing — perhaps a day or two shorter, slightly heavier, or with a harsher PMS week. FSH is usually still normal but may be rising on cycle day 2–5.
- Early Perimenopause (Stage -2): Persistent cycle-length variability of 7 days or more compared with your personal baseline. Your 28-day cycle becomes a 24-day cycle one month, a 35-day cycle the next. This is often the first clear signal.
- Late Perimenopause (Stage -1): A skipped period of 60 days or more. You may go three months without bleeding, then have a heavy flood. Hot flashes and night sweats become more common here. This stage typically lasts one to three years.
- Menopause (Stage 0): The final menstrual period, defined only in retrospect after 12 consecutive months of no bleeding. Average age in the U.S. is 51; the normal range is roughly 45 to 55.
- Early Postmenopause (Stage +1): The first 5–8 years after your final period. Vasomotor symptoms often peak here before gradually easing.
Primary Ovarian Insufficiency (POI) is a separate diagnosis: menopause before age 40. It affects roughly 1% of women and does warrant hormonal testing (see below).
The Symptom Constellation
Perimenopause is not just hot flashes. It is a system-wide recalibration that touches nearly every organ that has estrogen receptors — which is nearly every organ. The typical constellation:
- Menstrual changes. Shorter cycles first, then longer and skipped cycles. Heavy bleeding, clotting, and flooding are common because anovulatory cycles produce unopposed estrogen that thickens the endometrium.
- Vasomotor symptoms (VMS). Hot flashes and night sweats. Roughly 75–80% of women experience them; for about a third they are severe. Median duration is 7.4 years according to the SWAN study — far longer than the "a year or two" many women are told to expect.
- Sleep disruption. Classic pattern: falling asleep fine, waking at 2–4 a.m. wide awake, sometimes with a sweat. Even without overt night sweats, estrogen fluctuations destabilize sleep architecture.
- Mood changes. New or worsened anxiety, irritability, low mood, and rage episodes. Women with a history of PMS, postpartum depression, or premenstrual dysphoric disorder (PMDD) are at higher risk. This is biology, not weakness.
- Brain fog. Word-finding trouble, slower recall, losing your train of thought mid-sentence. Objective cognitive testing in SWAN confirmed measurable dips in processing speed and verbal memory that typically recover post-menopause.
- Joint and muscle aches. The "perimenopausal arthralgia" that shows up in shoulders, hips, hands, and knees without any injury. Estrogen modulates cartilage and tendon metabolism; its fluctuation produces genuine musculoskeletal pain.
- Intensified PMS. Many women describe their old two-day PMS expanding into a 10–14-day luteal misery. This is because estrogen peaks are higher and progesterone is often lower — a wider hormonal swing each cycle.
- Other: heart palpitations, migraines (new or worsened), dry eyes, dry mouth, new skin itchiness, hair thinning, urinary urgency, and a decline in vaginal lubrication (the early edge of genitourinary syndrome of menopause).
Why FSH and Estradiol Testing Misleads
Here is the core problem. A blood test captures one moment. Perimenopause is defined by variability over time. It is like trying to diagnose a choppy sea by taking a single photograph of one wave.
Follicle-stimulating hormone (FSH) rises when the ovary stops responding to normal pituitary signaling. Many references cite a threshold of FSH > 25 IU/L on cycle day 2–5 as suggestive of the menopause transition. But in perimenopause, FSH can be 8 one week and 40 the next. A woman with severe hot flashes and four months of missed periods can have a "premenopausal" FSH of 12 on the day she gets tested, and a woman with regular cycles can have an "elevated" FSH of 30. Neither result tells you what is happening over the course of a month, much less a year.
Estradiol (E2) is even worse as a snapshot. In perimenopause, estradiol often overshoots premenopausal levels during erratic ovulations before eventually declining. A single estradiol of 120 pg/mL does not mean "you are fine." It may mean "you caught the crest of the wave." Two weeks later the same woman might measure 25 pg/mL with a hot flash.
The North American Menopause Society (NAMS) and the Endocrine Society are both explicit: in a woman over 45 with classic symptoms and cycle changes, the diagnosis of perimenopause is clinical. Routine FSH and estradiol testing is not recommended and frequently causes harm by falsely reassuring women that "nothing is wrong."
Anti-Müllerian hormone (AMH) is sometimes proposed as a better marker because it declines more smoothly. AMH can predict the approximate time until final menstrual period in research cohorts, but it still does not change day-to-day management for a symptomatic woman. It is useful for fertility planning, not for perimenopause diagnosis.
When Testing Actually Helps
Hormonal testing is not worthless — it is just narrow. The specific situations where it earns its keep:
- Suspected Primary Ovarian Insufficiency (POI), under age 40. Amenorrhea or markedly irregular cycles plus menopausal symptoms in a woman under 40 is a different clinical situation with long-term cardiovascular, bone, and neurologic implications. Two FSH measurements > 25 IU/L at least one month apart, along with low estradiol, support POI. This diagnosis changes treatment (HRT is strongly recommended at least until the average age of natural menopause).
- After hysterectomy (with ovaries intact). Without periods to track, cycle-based diagnosis is impossible. Serial FSH and symptom review can help time the transition and HRT decisions.
- Contraception decisions in the late 40s and early 50s. A woman who has been on a hormonal contraceptive for years and wants to stop may use FSH (measured off-pill for 4–6 weeks) to estimate whether pregnancy is still possible. Two FSH values > 30 IU/L a few weeks apart in a woman over 50 who has been off hormonal contraception suggest contraception can be discontinued — though guidelines differ.
- Endometrial bleeding that is abnormal. Here testing is not for hormones but for cause: endometrial biopsy, pelvic ultrasound, and sometimes thyroid panel. Heavy, prolonged, intermenstrual, or postcoital bleeding deserves evaluation, not dismissal as "just perimenopause."
- Atypical presentations. Young age, rapid progression, or symptoms that do not fit — testing helps narrow the differential.
Overlap Conditions That Mimic Perimenopause
One reason perimenopause is under-diagnosed and over-diagnosed is that several common conditions produce an almost identical symptom picture. A good workup rules these out before assuming every symptom is hormonal — and before assuming nothing is hormonal. Ask for:
- Thyroid panel (TSH, free T4, and ideally free T3 + TPO antibodies). Hypothyroidism and Hashimoto's cause fatigue, weight gain, cold intolerance, depression, hair loss, menstrual irregularity, and brain fog. Hyperthyroidism causes heat intolerance, palpitations, anxiety, sleep disruption, and weight loss. Both are common in women in their 40s. See Thyroid Disorders.
- Ferritin and a full iron panel. Heavy perimenopausal bleeding drives iron stores down. Low ferritin (below 30–50 ng/mL in most lab frameworks) produces fatigue, brain fog, hair shedding, restless legs, and exercise intolerance — all indistinguishable from perimenopause at first glance.
- Vitamin B12 and folate. B12 deficiency causes fatigue, paresthesias, memory complaints, mood changes, and palpitations. Long-term metformin use, PPI use, vegan/vegetarian diets, and atrophic gastritis raise the risk.
- Vitamin D (25-hydroxy). Deficiency (< 30 ng/mL) contributes to joint aches, low mood, fatigue, and sleep disruption.
- Fasting glucose and HbA1c. Insulin resistance and early type 2 diabetes produce fatigue, weight shifts, and brain fog.
- Sleep apnea screening. Women are chronically under-diagnosed. Midlife weight gain plus estrogen decline increases the risk; classic "hot flash waking" can actually be an apnea arousal. See Insomnia.
- Depression and anxiety. Not mutually exclusive with perimenopause — the two amplify each other. Both deserve treatment in their own right.
A sensible baseline lab request for a woman in early perimenopause: TSH, free T4, ferritin, CBC, vitamin B12, 25-OH vitamin D, HbA1c, comprehensive metabolic panel. See the Hormone Panel page for which hormone tests are worth ordering and which are not.
A Practical 3-Month Symptom Tracker
This is the single most valuable tool you can bring to a clinician visit. Three months of daily data beats any blood test for diagnosing perimenopause and for judging whether HRT or another intervention is working. It also protects you from the common experience of being told "your labs look fine" when your life clearly does not.
Keep it simple enough that you will actually do it. A notebook, a phone notes app, or a spreadsheet all work. Each day, record the following on a 0–3 scale (0 = none, 1 = mild, 2 = moderate, 3 = severe):
- Hot flashes (count the number during the day)
- Night sweats (count the number of wake-ups)
- Sleep quality (0 = great, 3 = awful)
- Mood / irritability
- Anxiety
- Brain fog / concentration
- Joint aches
- Fatigue
- Libido (0–3 where 0 = none, 3 = normal-for-you)
- Bleeding (none / spotting / light / medium / heavy / flooding)
Each month also note:
- Start and end dates of any bleeding (cycle length is the "first day of one period to first day of the next").
- Any migraines, palpitations, or unusual symptoms.
- Alcohol, caffeine, and exercise patterns (hot flashes and sleep both respond).
- Any medication changes.
After three months, look at the data as a whole. You will see patterns that no single day reveals: cycles that used to be 28 now swinging 24–36; hot flash counts clustered in the week before a period; sleep collapsing during the luteal phase; mood scores tracking inversely with cycle day. That pattern is your diagnosis. Bring it to your clinician and ask for a treatment discussion, not another FSH draw.
Cycle- and Symptom-Tracking Apps
If a spreadsheet is not your style, a number of apps do most of this work for you. No app is perfect, and privacy concerns are real — read the data policy before choosing one. Common options that include perimenopause-specific features:
- Clue — research-oriented, good cycle tracking and a specific perimenopause mode. Published data studies.
- Caria (formerly Stella) — built specifically around menopause symptom tracking and education.
- Balance (Newson Health) — UK-originated; symptom score generates a report you can print for appointments.
- MenoLife — symptom tracking with lifestyle correlations.
- Oura Ring or Apple Health — if you already wear a tracker, the temperature, sleep, and HRV data are genuinely useful adjuncts, particularly for night sweats and sleep fragmentation.
The app matters less than the consistency. Pick one you will open daily for 90 days.
When to Start HRT vs. Wait
The modern NAMS and international consensus is that for healthy women under 60 or within 10 years of their final menstrual period, the benefits of systemic hormone therapy generally outweigh the risks for moderate-to-severe symptoms. You do not need to "wait until you are fully postmenopausal." In fact, starting during perimenopause is appropriate when symptoms meaningfully impair sleep, mood, relationships, or work.
Reasonable thresholds to discuss HRT now rather than wait:
- Hot flashes or night sweats disrupting sleep several nights a week.
- New or worsened depression or anxiety linked to cycle timing.
- Genitourinary symptoms (vaginal dryness, painful sex, recurrent UTIs) — these respond best to vaginal estrogen specifically; see GSM & Vaginal Estrogen.
- Joint aches or migraines with a clear cyclical pattern.
- Severe perimenopausal PMS / PMDD that has not responded to other treatments.
- Early menopause (< 45) or POI (< 40) — here HRT is strongly recommended for bone, cardiovascular, and brain protection, not just symptom relief.
Reasonable reasons to wait or to choose a non-hormonal route first:
- Symptoms mild and manageable with lifestyle changes (sleep hygiene, exercise, alcohol reduction, weight management).
- A contraindication to systemic estrogen (history of estrogen-sensitive breast cancer, active thromboembolic disease, active liver disease) — see HRT Risks and Non-Hormonal Options.
- Unresolved abnormal bleeding — evaluate first, treat second.
- Personal preference after informed discussion of risk and benefit.
In perimenopause specifically, HRT often looks like a transdermal estradiol patch (see Estradiol Routes) combined with cyclic or continuous micronized progesterone (see Progesterone vs. Progestins). For women who still need contraception, a combined hormonal contraceptive or a levonorgestrel IUD plus low-dose estrogen is sometimes used instead. The point is that options exist, they can be started during perimenopause, and the decision is individual — not dictated by an FSH number.
Key Research Papers
- Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
- Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN). JAMA Intern Med. 2015;175(4):531–539.
- Randolph JF Jr, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96(3):746–754.
- Santoro N, et al. Menstrual cycle hormone changes in women traversing menopause: Study of Women's Health Across the Nation. J Clin Endocrinol Metab. 2017;102(7):2218–2229.
- European Society of Human Reproduction and Embryology (ESHRE) Guideline on the Management of Premature Ovarian Insufficiency (PubMed search).
PubMed Topic Searches
- STRAW+10 menopause staging criteria
- Perimenopause FSH variability and diagnosis
- SWAN study vasomotor symptom duration
- Primary ovarian insufficiency diagnosis and management
- Anti-Müllerian hormone and menopause prediction
- Perimenopause and depression or anxiety
- Perimenopause and sleep fragmentation
- Perimenopause cognition and "brain fog"
- Perimenopause symptom tracking and digital health apps
- Thyroid dysfunction and perimenopause symptom overlap